Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
250 participants needed
1 Location
Brief description of study
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who previously received Nefecon in Study Nef-301 will receive retreatment, whereas patients who previously received placebo in Study Nef-301 will be treatment naïve to Nefecon.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Kidney DIsease
-
Age: 18 years - 99 years
-
Gender: All
Male and Female ,18 Years and older, Patients that completed study Nef-301
Updated on
04 Aug 2024.
Study ID: 849736
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
